Nabriva Therapeutics plc
Nabriva Therapeutics plc
Your view on NBRVF
Overview
What the company does, where it operates, and who runs it.
About Nabriva Therapeutics plc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- H. Michael Hogan
- Headquarters
- Alexandra House, Dublin, IE
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- H. Michael Hogan
- Headquarters
- Alexandra House, Dublin, IE
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections.
The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.
It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections.
In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007.
Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Nabriva Therapeutics plc, and the rating behind it. NBRVF last traded at $0.0002; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Nabriva Therapeutics plc. Starting points for Nabriva Therapeutics plc: EPS -$21.32, beta -6.10 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Nabriva Therapeutics plc. Nabriva Therapeutics plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Nabriva Therapeutics plc. Trailing twelve-month EPS for Nabriva Therapeutics plc stands at -$21.32. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Nabriva Therapeutics plc. Nabriva Therapeutics plc has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Nabriva Therapeutics plc valued side by side against its closest peers. Nabriva Therapeutics plc is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Nabriva Therapeutics plc, and how their positions are changing. At a $646 market value, institutional positions materially move Nabriva Therapeutics plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Nabriva Therapeutics plc executives and directors. Shares of Nabriva Therapeutics plc have traded between $0.0000 and $0.0002 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Nabriva Therapeutics plc. Nabriva Therapeutics plc is a $646 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Nabriva Therapeutics plc. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Nabriva Therapeutics plc. Coverage tracks Nabriva Therapeutics plc within Biotechnology (Healthcare). Press releases and market coverage, newest first.